Mnemosyne Pharmaceuticals, Inc. is a privately-held, biotechnology company focused on the discovery and development of small molecule therapeutics for the neuropsychiatry market. The company's drug discovery efforts are focused on targeting the NMDA receptor, which is known to be the 'master' switch for learning and memory. Mnemosyne's lead program is for schizophrenia, and the company is exploring additional indications including Alzheimer's disease, recovery from stroke and traumatic brain injury, and attention deficit/hyperactivity disorder. The company is based in Providence, Rhode Island.

Key Contact